ALTH Allos Therapeutics, Inc. (MM)

WESTMINSTER, Colo., Oct. 31 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced that data evaluating the Company's product candidates EFAPROXYN (efaproxiral) and PDX (pralatrexate) have been accepted for presentation at the following scientific conferences: * American Society for Therapeutic Radiology and Oncology: Hak Choy, M.D., Chairman, Department of Radiation Oncology, University of Texas Southwestern Medical Center, is scheduled to present an updated survival analysis of data from a Phase 2 trial of EFAPROXYN in patients with locally advanced (Stage IIIA/B) non-small cell lung cancer in an oral presentation titled "Comparison of 5-Year Survival Between RTOG-94-10 and a Phase 2 Study of Induction Chemotherapy Followed by Efaproxiral + Radiotherapy in Patients with Locally Advanced NSCLC" on Monday, November 6. In addition, Huagang Hou, M.D., Research Assistant Professor of Radiology, Dartmouth Medical School, is scheduled to report findings from a pre-clinical study of EFAPROXYN in a slide presentation titled "Effects of repeated EFAPROXYN (TM) (efaproxiral) dosing, an allosteric hemoglobin modifier, on oxygenation and enhancement of radiotherapy in subcutaneous RIF-1 tumors, in mice" on Tuesday, November 7. * EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics: Owen O'Connor, M.D., Ph.D., Head of the Laboratory of Experimental Therapeutics for Lymphoproliferative Malignancies, Lymphoma and Development Chemotherapy Services, Memorial Sloan-Kettering Cancer Center, is scheduled to present updated data from an on-going Phase 1/2 study of PDX in patients with relapsed or refractory non-Hodgkin's lymphoma and Hodgkin's disease in a poster presentation titled "Clinical Experience with Pralatrexate (10-Propargyl-10-deazaaminopterin (PDX)), a Novel Antifolate with High Affinity for the Reduced Folate Carrier, in Patients with Chemotherapy Refractory Lymphoproliferative Malignancies" on Friday, November 10. Copies of the posters will be available on the Company's website, http://www.allos.com/, the day following each presentation and will be archived for 30 days. About Allos Therapeutics, Inc. Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company has two product candidates in late-stage clinical development: EFAPROXYN (efaproxiral), a radiation sensitizer currently under evaluation in a pivotal Phase 3 trial in women with brain metastases originating from breast cancer, and PDX (pralatrexate), a novel, next generation antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also evaluating RH1, a targeted chemotherapeutic agent, in a Phase 1 trial in patients with advanced solid tumors. For additional information, please visit the Company's website at http://www.allos.com/. Safe Harbor Statement The anticipated presentations will contain forward-looking statements that involve significant risks and uncertainties, including those to be discussed in the presentation and others that can be found in the "Risk Factors" section of the Company's Form 10-K for the year ended December 31, 2005 and in the Company's periodic reports on Form 10-Q and Form 8-K. The Company does not undertake any obligation to update any forward-looking statements contained in the anticipated presentation as a result of new information, future events or otherwise. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Jennifer Neiman Manager, Corporate Communications of Allos Therapeutics, +1-720-540-5227, Web site: http://www.allos.com/

Copyright